McPeake J R, O'Grady J G, Zaman S, Portmann B, Wight D G, Tan K C, Calne R Y, Williams R
Institute of Liver Studies, King's College Hospital, London, United Kingdom.
J Hepatol. 1993 Jun;18(2):226-34. doi: 10.1016/s0168-8278(05)80250-8.
Liver transplantation for primary hepatocellular carcinoma (HCC) has in general been complicated by high recurrence rates. In the present study results from experience of 87 patients were analyzed [56 cirrhotic, 31 non-cirrhotic, 6 with the fibrolamellar (FL) variant] in relation to curative potential. Sixty-two survived > 90 days and form the study cohort. Fifty-six had non-fibrolamellar HCC and, of these, 39 had discrete lesions, measuring 0.8-21 cm (median 5.0 cm) including 4 in whom the diagnosis was made after examination of the explanted liver; 23 had multifocal lesions (> 2 tumor masses). There was no tumor recurrence in the group of 14 cases with single dominant lesions measuring < 4 cm, whereas in the 15 cases with lesions of 4-8 cm the recurrence rate was 40%, and 78% in those > 8 cm and the multifocal lesions (n = 27, P = 0.0001). Five-year actuarial survival figures were 57.1%, 44.4% and 11.1% (P < 0.003) respectively. The mean survival times in patients who died of recurrence were: 4-8 cm, 3.3 years (range 10 months to 6.3 years); > 8 cm or multifocal, 13 months (3-25 months). Reduction of serum alpha-fetoprotein (AFP) to normal levels does not exclude a later recurrence (7 of 17 cases) and this was documented after maintenance of normal AFP levels for up to 29 months.(ABSTRACT TRUNCATED AT 250 WORDS)
原发性肝细胞癌(HCC)的肝移植通常因高复发率而变得复杂。在本研究中,分析了87例患者[56例肝硬化患者、31例非肝硬化患者、6例纤维板层样(FL)变异型患者]的治疗潜力相关经验。62例存活超过90天,构成研究队列。56例为非纤维板层样HCC,其中39例有孤立性病变,大小为0.8 - 21厘米(中位数5.0厘米),包括4例在检查切除的肝脏后确诊的;23例有多灶性病变(> 2个肿瘤块)。14例单个主要病变直径< 4厘米的患者组中无肿瘤复发,而15例病变直径为4 - 8厘米的患者复发率为40%,病变直径> 8厘米及多灶性病变患者(n = 27)的复发率为78%(P = 0.0001)。5年精算生存率分别为57.1%、44.4%和11.1%(P < 0.003)。死于复发的患者平均生存时间为:4 - 8厘米,3.3年(范围10个月至6.3年);> 8厘米或多灶性病变,13个月(3 - 25个月)。血清甲胎蛋白(AFP)降至正常水平并不能排除后期复发(17例中有7例),且在AFP正常水平维持长达29个月后有记录。(摘要截断于250字)